Lineage Cell Therapeutics Analyst Ratings: Bullish Sentiments, Average 12-Month Price Target at $3.4

Analysts' ratings for Lineage Cell Therapeutics (LCTX) vary from bullish to bearish, with 5 analysts providing evaluations. The current average 12-month price target is $3.4, with a high estimate of $9.00 and a low estimate of $2.00. Jason Kolbert of D. Boral Capital maintains a "Buy" rating with a $2.00 price target, while Joseph Pantginis of HC Wainwright & Co. also maintains a "Buy" rating with a $9.00 price target.

Analysts' ratings for Lineage Cell Therapeutics (LCTX) have varied significantly, ranging from bullish to bearish sentiments. Over the past 30 days, five analysts have provided their evaluations, with one analyst maintaining a bullish stance and the rest being neutral or bearish [1]. The current average 12-month price target is $3.4, with estimates ranging from $2.00 to $9.00 [1].

Jason Kolbert of D. Boral Capital maintains a "Buy" rating with a $2.00 price target, while Joseph Pantginis of HC Wainwright & Co. also maintains a "Buy" rating with a $9.00 price target [1]. These ratings reflect differing opinions on the company's future performance and potential market value.

The company's market capitalization is above the industry average, indicating strong confidence and market prominence [1]. However, Lineage Cell Therapeutics has faced challenges in revenue growth, with a growth rate lower than the average among peers in the Health Care sector [1]. Despite these challenges, the company's net margin is impressive, surpassing industry averages [1].

Analysts' ratings provide valuable insights into the market's perception of Lineage Cell Therapeutics. While some analysts maintain a positive outlook, others are more cautious. Investors should consider these varying opinions alongside the company's financial metrics to make informed decisions [1].

References:
[1] https://www.benzinga.com/insights/analyst-ratings/25/08/47366715/5-analysts-assess-lineage-cell-therapeutics-what-you-need-to-know